tradingkey.logo
tradingkey.logo
Search

Champions Oncology Inc

CSBR
Add to Watchlist
4.860USD
+0.140+2.97%
Close 10-26 16:00(ET)
67.65MMarket Cap
LossP/E TTM

About Champions Oncology Inc Company

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

Champions Oncology Inc Profile

Ticker SymbolCSBR
Company nameChampions Oncology Inc
IPO dateNov 30, 1988
CEOBrainin (Robert)
Number of employees213
Security typeOrdinary Share
Fiscal year-endNov 30
AddressOne University Plaza,
CityHACKENSACK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07601
Phone12018088400
Websitehttps://championsoncology.com
Ticker SymbolCSBR
IPO dateNov 30, 1988
CEOBrainin (Robert)

Company Executives of Champions Oncology Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Joel Ackerman
Mr. Joel Ackerman
Independent Director
Independent Director
1.13M
+6.20%
Mr. Joel Ackerman
Mr. Joel Ackerman
Independent Director
Independent Director
1.13M
+6.20%
Dr. Ronnie Morris, M.D.
Dr. Ronnie Morris, M.D.
Chairman of the Board
Chairman of the Board
858.88K
--
Dr. Ronnie Morris, M.D.
Dr. Ronnie Morris, M.D.
Chairman of the Board
Chairman of the Board
858.88K
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Director
Independent Director
767.04K
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Director
Independent Director
767.04K
--
Mr. Scott R. Tobin
Mr. Scott R. Tobin
Independent Director
Independent Director
--
-100.00%
Mr. Daniel N. (Dan) Mendelson
Mr. Daniel N. (Dan) Mendelson
Independent Director
Independent Director
--
--
Mr. David Miller, CPA
Mr. David Miller, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Robert (Rob) Brainin
Mr. Robert (Rob) Brainin
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Ackerman
Mr. Joel Ackerman
Independent Director
Independent Director
1.13M
+6.20%
Mr. Joel Ackerman
Mr. Joel Ackerman
Independent Director
Independent Director
1.13M
+6.20%
Dr. Ronnie Morris, M.D.
Dr. Ronnie Morris, M.D.
Chairman of the Board
Chairman of the Board
858.88K
--
Dr. Ronnie Morris, M.D.
Dr. Ronnie Morris, M.D.
Chairman of the Board
Chairman of the Board
858.88K
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Director
Independent Director
767.04K
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Director
Independent Director
767.04K
--

FAQs

Who are the top five shareholders of Champions Oncology Inc?

The top five shareholders of Champions Oncology Inc are: Mr. Joel Ackerman

How many institutions hold shares of Champions Oncology Inc (CSBR)?

As of 2026Q1, 61 institutions hold shares of Champions Oncology Inc, with a combined market value of approximately 6.66M, accounting for 47.97% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -413745.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.